Biotechnology company Revance Therapeutics is introducing a prestige aesthetics portfolio to the U.S. market, starting with its RHA Collection of hyaluronic acid dermal fillers—the first and only FDA-approved dermal fillers for correction of dynamic facial wrinkles and folds—as well as an integrated fintech platform called HintMD. Revance also plans to follow those launches with the debut of DaxibotulinumtoxinA for Injection—formulated for the treatment of glabellar lines—once it receives FDA approval later this year. In preparation for the launches, not only did the company establish the safety and efficacy of the RHA dermal fillers through multiple clinical studies, but also recently completed onboarding and training process for its field force team, which has over 100 members. Says Dustin S. Sjuts, chief commercial officer of Revance Therapeutics. “Revance is positioned to re-energize the aesthetics industry with the creation of a prestige category of innovative products and services and elevated customer and patient experiences available through select practices.”
The RHA Collection is now available to select practices. More product information and updates for interested healthcare professionals can be found here.